top partner

for CFD

Investors had the weekend to think about the big stock market rally that they’ve watched over the past couple of weeks, and in general, the mood coming into the new week was still relatively good. Stock indexes generally eased lower, but not by a huge amount, and sentiment among market participants still seems strong.

That didn’t prevent a couple of stocks from having some larger moves. (NASDAQ: MNDY) lived up to its name by releasing its latest financial results Monday morning, and shareholders generally liked what they saw. Unfortunately, you can’t say the same thing about biotech stock Verve Therapeutics (NASDAQ: VERV), which disappointed its investors with some downbeat news. keeps working harder

Shares of were up 11% early in the session. The work operating system software provider reported third-quarter financial results that confirmed that it remains on a healthy growth trajectory. posted third-quarter revenue of $189 million, up 38% year over year. The software company reported a profit even under generally accepted accounting principles, and adjusted net income soared 12-fold to $33 million. That worked out to adjusted earnings of $0.64 per share.

Co-founders and co-CEOs Eran Zinman and Roy Mann pointed to some key highlights during the period. has been working on its mondayDB database infrastructure platform to complement its current software offerings, and the two leaders see rolling out the final product sooner than previously expected. At the same time, has been efficient from a business perspective, boosting margins and reaching profitability expeditiously. also sees a brighter future, with new guidance for sales growth of 39% to 40% in 2023 and 31% to 32% for the fourth quarter. With strong net dollar retention rates above 110% and a 57% jump in customers spending at least $50,000 annually on the platform, doesn’t seem to face any challenges with strong demand.

Verve faces some safety questions

Meanwhile, shares of Verve Therapeutics plunged 44% Monday morning. The biotech company reported interim data for a key trial, but investors weren’t happy with all of the early results.

Verve’s phase 1b clinical trial of its VERVE-101 treatment for high levels of low-density lipoprotein cholesterol (LDL-C) did have some encouraging results. Verve’s efficacy analysis showed that a single infusion of the treatment was sufficient to show reductions in a key protein level, which suggested that the gene-editing therapy had the intended impact. A month after treatment, there were observations of reduced LDL-C levels.

However, shareholders weren’t pleased at two serious adverse events noted in the safety analysis of the treatment. One patient had a fatal cardiac arrest, but the investigators concluded that it wasn’t related to VERVE-101. However, one patient’s myocardial infraction was potentially the result of the treatment, although investigators hadn’t been aware of chest pain symptoms prior to administering that patient.

Despite the independent data and safety monitoring board recommending the trial continue, investors never like to see bad news related to safety in early clinical trials. To restore confidence, Verve will likely have to see much more favorable safety results as its trials progress.

10 stocks we like better than
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 6, 2023

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends The Motley Fool has a disclosure policy.

Read the full story: Read More“>

Blog powered by G6

Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.

For any inquiries, please contact [email protected]